COST-EFFECTIVENESS ANALYSIS OF GASTRITIS THERAPY IN AN AIR FORCE HOSPITAL IN BANDUNG, INDONESIA

RIANI TANJUNG; YULIA WARDATI; DINI NUR AZIZAH; BHEKTI PRATIWI; RESMI MUSTARICHIE; NYI MEKAR SAPTARINI

doi:10.22159/ijap.2022.v14s4.PP06

Authors

RIANI TANJUNG Department of Accounting, Vocational School, Universitas Logistik and Bisnis Internasional, West Java, Indonesia, 40151
YULIA WARDATI Department of Pharmacy, Faculty of Mathematic and Natural Sciences, Al Ghifari University, West Java, Indonesia, 40293
DINI NUR AZIZAH Department of Pharmacy, Faculty of Mathematic and Natural Sciences, Al Ghifari University, West Java, Indonesia, 40293
BHEKTI PRATIWI School of Pharmacy, Bandung Institute of Technology, West Java, Indonesia, 40116
RESMI MUSTARICHIE Department of Pharmaceutical Analysis and Medicinal Chemistry, Faculty of Pharmacy, Universitas Padjadjaran, West Java, Indonesia, 45363
NYI MEKAR SAPTARINI Department of Pharmaceutical Analysis and Medicinal Chemistry, Faculty of Pharmacy, Universitas Padjadjaran, West Java, Indonesia, 45363

DOI:

https://doi.org/10.22159/ijap.2022.v14s4.PP06

Keywords:

LOS, Leukocytes, Medicine, Pharmacoeconomic, Sensitivity test

Abstract

Objective: This study aimed to analyze the cost-effectiveness of gastritis treatment and the influence factors of cost-effectiveness at an air force hospital in Bandung, West Java, Indonesia.

Methods: Data were collected retrospectively from patient medical records and Hospital Information System (HIS). This study was conducted from August to October 2020. Cost data includes total costs from the perspective of the hospital (health care) and the perspective of the Social Security Administrator for Health (Badan Penyelenggara Jaminan Sosial, BPJS, payer) based on Indonesian-Case Based Groups rates. Outcomes in this study were length of stay (LOS) and leukocytes.

Results: There were 129 patients in inpatient units in the year of 2018-2019. The medicines for gastritis therapy were omeprazole and ranitidine injection and lansoprazole and ulsidex tablet. The most cost-effective therapy based on LOS was ranitidine injection, while based on reducing leukocytes was, ranitidine injection from the payer's perspective and lansoprazole from healthcare perspective.

Conclusion: There was no significant cost difference between the four treatment options. The sensitivity test showed that the influence factor of the Incremental Cost Effectiveness Ratio (ICER) value was decreased leukocytes.

Downloads

Download data is not yet available.

References

Dore MP, Graham DY. Ulcers and gastritis. Endoscopy. 2010;42(1):38-41. doi: 10.1055/s-0029-1215314, PMID 19904699.

Szabo S, Trier JS, Frankel PW. Sulfhydryl compounds may mediate gastric cytoprotection. Science. 1981;214(4517):200-2. doi: 10.1126/science.7280691, PMID 7280691.

The Ministry of Health of the Republic of Indonesia. Center for data and information on non-communicable diseases, Jakarta: Ministry of Health of the Republic of Indonesia; 2012.

Fauci AS, Kasper DL, Longo DL, Braunwald E, Hauser SL, Jameson JL. 17th ed. Harrison’s Intern Med. 2008;38(12):932-46.

Andersen LP. Colonization and infection by Helicobacter pylori in humans. Helicobacter. 2007;12Suppl 2:12-5. doi: 10.1111/j.1523-5378.2007.00574.x, PMID 17991171.

Wells BG, Dipiro J, Schwinghammer TL, DiPiro CV. Pharmacotherapy handbook. 9th ed. New York: McGraw-Hill Companies, Inc; 2015.

Grosse SD. Assessing cost-effectiveness in health care: the history of the $50,000 per QALY threshold. Value Health. 2008;8:165-78.

Tanjung R, Wardati Y, Saptarini NM. Cost-effectiveness analysis of typhoid fever inpatient in the private hospital in Subang, Indonesia. Drug Invent Today. 2020;14(2):344-7.

Tanjung R, Wardati Y, Saptarini NM. Cost-effectiveness analysis of prolanis of type 2 diabetic patients in three community health centers in Bandung, Indonesia. Int J Appl Pharm. 2021;13Special Issue 3:28-31.

Liver Tox. Clinical and research information on drug-induced liver injury. Bethesda: National Institute of Diabetes and Digestive and Kidney Diseases. Proton Pump Inhibitors. 2012. PMID 31643228.

Malfertheiner P, Kandulski A, Venerito M. Proton-pump inhibitors: understanding the complications and risks. Nat Rev Gastroenterol Hepatol. 2017;14(12):697-710. doi: 10.1038/nrgastro.2017.117, PMID 28930292.

Sakamoto Y, Shimoyama T, Nakagawa S, Mikami T, Fukuda S. Proton pump inhibitor treatment decreases the incidence of upper gastrointestinal disorders in elderly Japanese patients treated with NSAIDs. Intern Med. 2014;53(11):1107-11. doi: 10.2169/internal medicine.53.2159, PMID 24881732.

France MM, Turner JR. The mucosal barrier at a glance. J Cell Sci. 2017;130(2):307-14. doi: 10.1242/jcs.193482, PMID 28062847.

Du Y, Bai Y, Xie P, Fang J, Wang X, Hou X. Chronic gastritis in China: a national multi-center survey. BMC Gastroenterol. 2014;14(14):21. doi: 10.1186/1471-230X-14-21, PMID 24502423.

Vincent K. Gastritis and peptic ulcer disease. In: Kellerman R, Rakel D, editors. Conn’s current therapy. Amsterdam, Netherlands: Elsevier; 2021. p. 210-13.

Agarwal A, Gupta S, Sharma RK. Role of oxidative stress in female reproduction. Reprod Biol Endocrinol. 2005;3:28. doi: 10.1186/1477-7827-3-28, PMID 16018814.

Schfler WC. Statistics for biology, pharmacy, medicine and related sciences. Bandung, Indonesia: ITB Publisher; 1987.

Chang YW, Ko WJ, Oh CH, Park YM, Oh SJ, Moon JR. Clarithromycin resistance and female gender affect Helicobacter pylori eradication failure in chronic gastritis. Korean J Intern Med. 2019;34(5):1022-9. doi: 10.3904/kjim.2018.054, PMID 29898576.

Regulation of the Minister of Health of the Republic of Indonesia. Vol. 69 of. Jakarta, Indonesia: Basic Book Company Health Research; 2013. p. 2013.

Jin JF, Zhu LL, Chen M, Xu HM, Wang HF, Feng XQ. The optimal choice of medication administration route regarding intravenous, intramuscular, and subcutaneous injection. Patient Prefer Adherence. 2015;9:923-42. doi: 10.2147/PPA.S87271, PMID 26170642.

Kaplan Machlis B, Spiegler GE, Zodet MW, Revicki DA. Effectiveness and costs of omeprazole vs ranitidine for treatment of symptomatic gastroesophageal reflux disease in primary care clinics in West Virginia. Arch Fam Med. 2000;9(7):624-30. doi: 10.1001/archfami.9.7.624, PMID 10910310.

Pece S, Giuliani G, DiLeo A, Fumarola D, Antonaci S, Jirillo E. Role of lipopolysaccharide and related cytokines in helicobacter pylori infection. Recent Prog Med. 1997;88:237-41.

Fasseas P, Leybishkis B, Rocca G. Omeprazole versus ranitidine in the medical treatment of acute upper gastrointestinal bleeding: assessment by early repeat endoscopy. Int J Clin Pract. 2001;55(10):661-4. PMID 11777288.

Hofbauer R, Losert H, Gmeiner B, Wagner O, Kapiotis S, Frass M. Inhibitory effect of omeprazole on transmigration of leukocytes through endothelial cell monolayers and leukocyte adhesion. Microvasc Res. 2000;59(1):169-71. doi: 10.1006/mvre.1999.2196, PMID 10625584.

Niv Y. Effectiveness of omeprazole-versus lansoprazole-based triple therapy for Helicobacter pylori eradication. Dig Dis Sci. 2005;50(5):839-41. doi: 10.1007/s10620-005-2649-y, PMID 15906754.

Stalhammar NO, Carlsson J, Peacock R, Muller Lissner S, Bigard MA, Porro GB. Cost effectiveness of omeprazole and ranitidine in intermittent treatment of symptomatic gastro-oesophageal reflux disease. Pharmacoeconomics. 1999;16(5 Pt 1):483-97. doi: 10.2165/00019053-199916050-00006, PMID 10662395.

Drummond MF, Sculpher MJ, Torrance GW, O’Brien BJ, Stoddant GL. Methods for the economic evaluation of health care programmes. UK: Oxford University Press; 2005.

Gray AM, Clarke PM, Wolstenholme JL, Wordsworth S. Applied methods of cost effectiveness analysis in health care. UK: Oxford University Press; 2011.